OliX Pharmaceuticals Inc. signed a memorandum of understanding (MOU) with DynamiCure Biotechnology for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum recently held in Boston, Massachusetts. The Ministry of Health and Welfare of Korea and Korea Health Industry Development Institute hosted Korea-US Digital·BioHealth Business Forum on April 27 in Boston. OliX took part in the forum as it was selected as one of the five Korean companies to sign a collaboration agreement with a U.S. company.

At the event, OliX inked an MOU with DynamiCure to agree on innovative technological collaboration for developing RNA-ADC therapeutics. DynamiCure Biotechnology specializes in developing oncology drugs and autoimmune therapies with antibody technology. The company owns an anticancer pipeline, which is currently in the clinical stage, with a mechanism of targeting a receptor that affects the abnormal development of tumor vasculature.